Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)

OBJECTIVE: In the primary analysis of the phase 2b VESTA study, oral fezolinetant reduced frequency and severity of menopausal vasomotor symptoms (VMS) compared with placebo. This secondary analysis evaluates effects of fezolinetant on responder rates and patient-reported outcomes (PROs). METHODS: I...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Menopause
Autores principales: Santoro, Nanette, Waldbaum, Arthur, Lederman, Samuel, Kroll, Robin, Fraser, Graeme L., Lademacher, Christopher, Skillern, Laurence, Young, James, Ramael, Steven
Formato: Artigo
Lenguaje:Inglês
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Studies
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709922/
https://ncbi.nlm.nih.gov/pubmed/32769757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001621
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares